Latest news with #Tillet
Yahoo
30-05-2025
- Entertainment
- Yahoo
Church hopes live music will put venue 'on the map'
A church which doubles as a music venue to help pay its bills is hosting a new series of concerts which it hopes will put it on the map. St Peter's Church in Parkstone often plays host to tribute acts and DJs but a new partnership will see it host some "very special" gigs by international artists. Church rector, the Reverend Mike Trotman, said the concert series - In the Nave - would be "carefully navigated". "We don't want anything too sweary," he said. "We need to tap in to what makes this a unique and special place." The rector, who describes himself as a music lover, said he began exploring the idea of hosting concerts after hearing about Mr Kyps, a popular music venue in Parr Street which closed in 2018. "There's a real appetite for live music," he said. "I genuinely think we are doing something very special." The concerts, for up to 400 people, are being organised by music management firm Warm. Founder Ali Tillet said he wanted to "put the venue on the map for amazing artists to come and play year in, year out". The first gig will feature Annie and the Caldwells, a soul band from Mississippi, signed to David Byrne's LukaBop record label. "It's great to have them coming," said Mr Tillet. "They will definitely bring the energy to the church because they are from a church background in America as well." Mr Tillet said he was "hugely excited" about the project. "If we can get the artists I'm potentially going to have in the next 18 months to come and play, they will be moments that, if you are able to get tickets to those shows, you will remember it for a long time." You can follow BBC Dorset on Facebook, X (Twitter), or Instagram. Radiohead reimagined with classical twist in home city Moshpits and pulpits as minster hosts metal gig St Peter's Parkstone In the Knave Annie and the Caldwells
Herald Sun
02-05-2025
- Business
- Herald Sun
Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. First patient dosed at lead trial site, Southside Cancer Care. Phase 1 trial to determine safety, tolerability and pharmacokinetic data, plus maximum tolerated combined dose of RC220 with chemotherapeutic doxorubicin. Up to 33 patients to be recruited in first stage across sites in Australia, Hong Kong and South Korea. Special Report: The first site in Race Oncology's Phase 1 clinical trial of RC220 in advanced solid tumours has been activated with the first patient dosed safely at Southside Cancer Care Centre in Miranda, NSW. No vein inflammation or any other adverse events were reported, clearing the way for Race Oncology (ASX:RAC) to dose more patients in this first stage of the trial. The company's goal is to establish the safety, tolerability and pharmacokinetic data – in other words, the way the drug is absorbed, distributed, metabolised and excreted – as well as the maximum tolerated combined dose of RC220 in combination with powerful chemotherapy drug doxorubicin. A second trial site at the Gosford and Wyong hospitals also recently opened for patient enrolment, with up to another 32 patients to be enrolled at sites across Australia, Hong Kong and South Korea. Race Oncology CEO Dr Daniel Tillet said the safe dosing of this first patient was a major milestone for the company, and the beginning of an important program that would assess the safety, tolerability and therapeutic potential of RC220. 'We are grateful to all the patients, investigators and clinical teams who have made this trial possible,' Tillet said. 'I would also like to thank our shareholders for their strong and loyal support that has enabled us to bring RC220 to patients in the clinic." Why combine chemotherapy with RC220? RC220 is a small molecule drug found to enhance the cancer-killing activity of chemotherapy doxorubicin in 85% of 143 cancer cell lines screened by RAC. The drug has been investigated in more than 50 clinical trials where it was found to have an effect in a range of solid and blood-based cancers including breast, ovarian, kidney, lung and various leukaemias including acute myeloid leukaemia. Importantly, RC220 demonstrates an anti-cancer effect with less cardiotoxicity compared to chemotherapy anthracyclines like doxorubicin, therefore offering a potential cardioprotective effect that could reduce damage to the heart during chemotherapy treatments, while enhancing the drugs' cancer killing effect. In Stage 2 of the trial, RAC will use an optimal dosage of RC220 in combination with doxorubicin – determined by an analysis of Phase 1 data – in 20 additional patients to establish further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. As the trial is open-label, patient outcomes will be available for assessment as soon as treatment is complete. RAC intends to announce progress updated on a regular basis, but not on an individual patient level. This article was developed in collaboration with Race Oncology, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
